117TH CONGRESS 1ST SESSION

H. R. 1873

To educate health care providers and the public on biosimilar biological products, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

March 12, 2021

Mr. Bucshon (for himself and Mr. Peters) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To educate health care providers and the public on biosimilar biological products, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Advancing Education
- 5 on Biosimilars Act of 2021".
- 6 SEC. 2. EDUCATION ON BIOLOGICAL PRODUCTS.
- 7 Subpart 1 of part F of title III of the Public Health
- 8 Service Act (42 U.S.C. 262 et seq.) is amended by adding
- 9 at the end the following:

1 "SEC. 352A. EDUCATION ON BIOLOGICAL PRODUCTS.

2	"(a) Internet Website.—
3	"(1) In General.—The Secretary may main-
4	tain and operate an internet website to provide edu-
5	cational materials for health care providers, patients,
6	and caregivers, regarding the meaning of the terms,
7	and the standards for review and licensing of, bio-
8	logical products, including biosimilar biological prod-
9	ucts and interchangeable biosimilar biological prod-
10	ucts.
11	"(2) Content.—Educational materials pro-
12	vided under paragraph (1) may include—
13	"(A) explanations of key statutory and
14	regulatory terms, including 'biosimilar' and
15	'interchangeable', and clarification regarding
16	the use of interchangeable biosimilar biological
17	products;
18	"(B) information related to development
19	programs for biological products, including bio-
20	similar biological products and interchangeable
21	biosimilar biological products and relevant clin-
22	ical considerations for prescribers, which may
23	include, as appropriate and applicable, informa-
24	tion related to the comparability of such biologi-
25	cal products:

1	"(C) an explanation of the process for re-
2	porting adverse events for biological products,
3	including biosimilar biological products and
4	interchangeable biosimilar biological products;
5	and
6	"(D) an explanation of the relationship be-
7	tween biosimilar biological products and inter-
8	changeable biosimilar biological products li-
9	censed under section 351(k) and reference
10	products (as defined in section 351(i)), includ-
11	ing the standards for review and licensing of
12	each such type of biological product.
13	"(3) FORMAT.—The educational materials pro-
14	vided under paragraph (1) may be—
15	"(A) in formats such as webinars, con-
16	tinuing education modules, videos, fact sheets,
17	infographics, stakeholder toolkits, or other for-
18	mats as appropriate and applicable; and
19	"(B) tailored for the unique needs of
20	health care providers, patients, caregivers, and
21	other audiences, as the Secretary determines
22	appropriate.
23	"(4) Other information.—In addition to the
24	information described in paragraph (2), the Sec-
25	retary shall continue to publish—

1	"(A) the action package of each biological
2	product licensed under subsection (a) or (k) of
3	section 351; or
4	"(B) the summary review of each biological
5	product licensed under subsection (a) or (k) of
6	section 351.
7	"(5) Confidential and trade secret in-
8	FORMATION.—This subsection does not authorize
9	the disclosure of any trade secret, confidential com-
10	mercial or financial information, or other matter de-
11	scribed in section 552(b) of title 5.
12	"(b) Continuing Education.—The Secretary shall
13	advance education and awareness among health care pro-
14	viders regarding biological products, including biosimilar
15	biological products and interchangeable biosimilar biologi-
16	cal products, as appropriate, including by developing or
17	improving continuing education programs that advance
18	the education of such providers on the prescribing of, and
19	relevant clinical considerations with respect to, biological
20	products, including biosimilar biological products and
21	interchangeable biosimilar biological products.".